<DOC>
	<DOC>NCT01125566</DOC>
	<brief_summary>To investigate the efficacy and safety of BIBW 2992 in combination with vinorelbine i.v. chemotherapy as treatment in patients with HER2-overexpressing, metastatic breast cancer, who failed one prior trastuzumab (HerceptinÂ®) treatment</brief_summary>
	<brief_title>LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Inclusion criteria: Histologically confirmed diagnosis of HER2overexpression breast cancer Stage IV metastatic disease Must have progressed on one prior trastuzumab treatment no more than one prior trastuzumab based therapy regimen (either adjuvant or firstline) Must have received anthracycline and/or taxane based chemotherapy for adjuvant treatment of breast cancer or firstline treatment of metastatic breast cancer Must have (archived) tumour tissue sample available for central reassessment of HER2status At least one measurable lesion according to RECIST 1.1. ECOG score of 0 or 1 . Exclusion criteria: Prior treatment with EGFR/HER2targeted small molecules or antibodies other than trastuzumab Prior treatment with vinorelbine Known preexisting interstitial lung disease Active brain metastases History or presence of clinically relevant cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable angina or poorly controlled arrhythmia. Myocardial infarction within 6 months prior to randomisation. Cardiac left ventricular function with resting ejection fraction of less than 50%. Patients unable to comply with the protocol. Any contraindications for therapy with vinorelbine or trastuzumab. Known hypersensitivity to BIBW 2992 or the excipients of any of the trial drugs. Use of any investigational drug within 4 weeks of randomisation. Inadequate hepatic, renal and haematologic organ function</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>